Table of Contents Author Guidelines Submit a Manuscript
International Journal of Rheumatology
Volume 2011 (2011), Article ID 214013, 7 pages
http://dx.doi.org/10.1155/2011/214013
Review Article

B-Cell Depletion Therapy in Systemic Sclerosis: Experimental Rationale and Update on Clinical Evidence

Division of Rheumatology, Department of Internal Medicine, Patras University Hospital, University of Patras Medical School, Rion, 26504 Patras, Greece

Received 24 February 2011; Revised 4 June 2011; Accepted 7 June 2011

Academic Editor: Laura K. Hummers

Copyright © 2011 Dimitrios Daoussis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. P. Tashkin, R. Elashoff, P. J. Clements et al., “Cyclophosphamide versus placebo in scleroderma lung disease,” The New England Journal of Medicine, vol. 354, no. 25, pp. 2655–2666, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. B. Terrier, Z. Amoura, P. Ravaud et al., “Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French autoimmunity and rituximab registry,” Arthritis and Rheumatism, vol. 62, no. 8, pp. 2458–2466, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. J. H. Stone, P. A. Merkel, R. Spiera et al., “Rituximab versus cyclophosphamide for ANCA-associated vasculitis,” The New England Journal of Medicine, vol. 363, no. 3, pp. 221–232, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. S. L. Hauser, E. Waubant, D. L. Arnold et al., “B-cell depletion with rituximab in relapsing-remitting multiple sclerosis,” The New England Journal of Medicine, vol. 358, no. 7, pp. 676–688, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. M. Fujimoto and S. Sato, “B Iymphocytes and systemic sclerosis,” Current Opinion in Rheumatology, vol. 17, no. 6, pp. 746–751, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Sato, M. Fujimoto, M. Hasegawa, K. Takehara, and T. F. Tedder, “Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis,” Molecular Immunology, vol. 41, no. 12, pp. 1123–1133, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. M. Hasegawa, “B lymphocytes: shedding new light on the pathogenesis of systemic sclerosis,” Journal of Dermatology, vol. 37, no. 1, pp. 3–10, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. F. A. Wollheim, “Is rituximab a potential new therapy in systemic sclerosis? New evidence indicates the presence of CD20-positive B-lymphocytes in scleroderma skin,” Journal of Clinical Rheumatology, vol. 10, no. 3, p. 155, 2004. View at Google Scholar · View at Scopus
  9. S. Saito, K. Kasturi, and C. Bona, “Genetic and immunologic features associated with scleroderma-like syndrome of TSK mice,” Current Rheumatology Reports, vol. 1, no. 1, pp. 34–37, 1999. View at Google Scholar · View at Scopus
  10. E. Saito, M. Fujimoto, M. Hasegawa et al., “CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse,” Journal of Clinical Investigation, vol. 109, no. 11, pp. 1453–1462, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. N. Asano, M. Fujimoto, N. Yazawa et al., “B lymphocyte signaling established by the CD19/CD22 loop regulates autoimmunity in the tight-skin mouse,” American Journal of Pathology, vol. 165, no. 2, pp. 641–650, 2004. View at Google Scholar · View at Scopus
  12. M. Odaka, M. Hasegawa, Y. Hamaguchi et al., “Autoantibody-mediated regulation of B cell responses by functional anti-CD22 autoantibodies in patients with systemic sclerosis,” Clinical and Experimental Immunology, vol. 159, no. 2, pp. 176–184, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. M. Hasegawa, Y. Hamaguchi, K. Yanaba et al., “B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis,” American Journal of Pathology, vol. 169, no. 3, pp. 954–966, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. T. Matsushita, M. Fujimoto, M. Hasegawa et al., “BAFF antagonist attenuates the development of skin fibrosis in tight-skin mice,” Journal of Investigative Dermatology, vol. 127, no. 12, pp. 2772–2780, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. A. Yoshizaki, Y. Iwata, K. Komura et al., “CD19 regulates skin and lung fibrosis via toll-like receptor signaling in a model of bleomycin-induced scleroderma,” American Journal of Pathology, vol. 172, no. 6, pp. 1650–1663, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. K. Komura, K. Yanaba, M. Horikawa et al., “CD19 regulates the development of bleomycin-induced pulmonary fibrosis in a mouse model,” Arthritis and Rheumatism, vol. 58, no. 11, pp. 3574–3584, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. S. Sato, M. Hasegawa, M. Fujimoto, T. F. Tedder, and K. Takehara, “Quantitative genetic variation in CD19 expression correlates with autoimmunity,” Journal of Immunology, vol. 165, no. 11, pp. 6635–6643, 2000. View at Google Scholar · View at Scopus
  18. S. Sato, M. Fujimoto, M. Hasegawa, and K. Takehara, “Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells,” Arthritis and Rheumatism, vol. 50, no. 6, pp. 1918–1927, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. N. Tsuchiya, K. Kuroki, M. Fujimoto et al., “Association of a functional CD19 polymorphism with susceptibility to systemic sclerosis,” Arthritis and Rheumatism, vol. 50, no. 12, pp. 4002–4007, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. T. Matsushita, M. Hasegawa, K. Yanaba, M. Kodera, K. Takehara, and S. Sato, “Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes,” Arthritis and Rheumatism, vol. 54, no. 1, pp. 192–201, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. M. Bielecki, K. Kowal, A. Lapinska, P. Bernatowicz, L. Chyczewski, and O. Kowal-Bielecka, “Increased production of a proliferation-inducing ligand (APRIL) by peripheral blood mononuclear cells is associated with antitopoisomerase I antibody and more severe disease in systemic sclerosis,” Journal of Rheumatology, vol. 37, no. 11, pp. 2286–2289, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. M. L. Whitfield, D. R. Finlay, J. I. Murray et al., “Systemic and cell type-specific gene expression patterns in scleroderma skin,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 21, pp. 12319–12324, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. R. Lafyatis, C. O'Hara, C. A. Feghali-Bostwick, and E. Matteson, “B cell infiltration in systemic sclerosis-associated interstitial lung disease,” Arthritis and Rheumatism, vol. 56, no. 9, pp. 3167–3168, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. N. K. Harrison, A. R. Myers, B. Corrin et al., “Structural features of interstitial lung disease in systemic sclerosis,” American Review of Respiratory Disease, vol. 144, no. 3, part 1, pp. 706–713, 1991. View at Google Scholar · View at Scopus
  25. V. Smith, J. T. Van Praet, B. Vandooren et al., “Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study,” Annals of the Rheumatic Diseases, vol. 69, no. 1, pp. 193–197, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. R. Lafyatis, E. Kissin, M. York et al., “B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis,” Arthritis and Rheumatism, vol. 60, no. 2, pp. 578–583, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. D. Daoussis, S. N. Liossis, A. C. Tsamandas et al., “Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study,” Rheumatology, vol. 49, no. 2, Article ID kep093, pp. 271–280, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. S. Bosello, M. De Santis, G. Lama et al., “B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial,” Arthritis research & therapy, vol. 12, no. 2, p. R54, 2010. View at Google Scholar · View at Scopus
  29. D. McGonagle, A. L. Tan, J. Madden et al., “Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab,” Rheumatology, vol. 47, no. 4, pp. 552–553, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. D. Daoussis, S. N. C. Liossis, A. C. Tsamandas et al., “Is there a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature,” Seminars in Arthritis and Rheumatism, vol. 40, no. 2, pp. 127–136, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. W. H. Yoo, “Successful treatment of steroid and cyclophosphamide-resistant diffuse scleroderma-associated interstitial lung disease with rituximab,” Rheumatology International, pp. 1–4, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. L. Brulhart, J. M. Waldburger, and C. Gabay, “Rituximab in the treatment of antisynthetase syndrome,” Annals of the Rheumatic Diseases, vol. 65, no. 7, pp. 974–975, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. M. Sem, O. Molber, M. B. Lund, and J. T. Gran, “Rituximab treatment of the anti-synthetase syndrome: a retrospective case series,” Rheumatology, vol. 48, no. 8, pp. 968–971, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. S. N. C. Liossis, A. Bounas, and A. P. Andonopoulos, “Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease,” Rheumatology, vol. 45, no. 8, pp. 1005–1008, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. D. Daoussis, S. N. Liossis, A. Tsamandas et al., “Efficacy and safety of rituximab in patients with diffuse scleroderma. An up to 2 years follow up study,” EULAR FRI0403, 2011. View at Google Scholar
  36. D. Daoussis, S. N. Liossis, A. Tsamandas, I. Antonopoulos, G. Yiannopoulos, and A. P. Andonopoulos, “The PDGF receptor is highly phosphorylated (activated) in scleroderma skin. Rituximab induced improvement of skin fibrosis in patients with scleroderma associates with a significant decrease in PDGF receptor phosphorylation,” EULAR FRI0426, 2011. View at Google Scholar
  37. S. N. Liossis and P. P. Sfikakis, “Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells,” Clinical Immunology, vol. 127, no. 3, pp. 280–285, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus